Sichuan Shuangma: In recent years, it has expanded into the biotech and scientific innovation sectors through direct investments and investments in venture capital funds.

NightAirdropper · 2026-03-11T22:40:37+00:00

Sichuan Shuangma responded on the investor relations platform regarding policy benefits related to biomedicine and the company's market capitalization management, stating that it will actively deploy in the biomedicine field and focus on market value management to enhance intrinsic value and competitiveness.

NightAirdropper

2026-03-11 22:40:37

Abstract generation in progress

Securities Star News, Sichuan Shuangma (000935) responded to investor questions on the investor relations platform on March 10.

Investor: The favorable policies for biotechnology from the Two Sessions—are they related to the company’s business?

Sichuan Shuangma Secretary: Hello, this year’s National Two Sessions government work report emphasizes developing the biopharmaceutical industry as a pillar industry, signaling an important policy move to accelerate industry upgrading. In recent years, the company has strategically invested in the biotech and innovative technology sectors through direct investments and venture capital funds. Moving forward, the company will continue to seize policy and industry opportunities, actively promote deep development and high-quality growth in the biopharmaceutical sector, continuously improve management and asset operation efficiency, focus on core value creation, and strive to generate more value and returns for shareholders. Thank you for your attention to the company.

Investor: The company’s market value is still less than the market value of the company’s private equity fund management. What is the target for market value management?

Sichuan Shuangma Secretary: Hello, the company attaches great importance to market value management, always aiming to enhance intrinsic value as its core goal. The company adheres to stable operations and performance growth as the foundation, optimizes business layout, strengthens core competitiveness, and improves development quality; at the same time, it continuously improves corporate governance, standardizes information disclosure, enhances investor relations management, and actively promotes market recognition and fair reflection of the company’s value. Thank you for your attention to the company.

The above content is compiled from publicly available information by Securities Star, generated by AI algorithms (Net Xin Suan Bei 310104345710301240019), and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.